Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava.

The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15% according to different reports and, so far, no one has analyzed in depth whether new oral anticoagulant agents (non-vitamin K oral anticoagulants [NOACs]) result in superior benefit compared with classic vitamin K antagonists (VKAs).

This study analyzed 962 patients. Among them, 326 received NOACs (33.9%) and 636 received VKAs (66.1%).

The primary endpoint at 12 months was a composite of all-cause mortality, acute myocardial infarction, and stroke.

Groups were similar: the mean age was 81 years, 52% of patients were women, the Society of Thoracic Surgeons (STS) score was 4.5%, and the CHA2DS2 VASC Score ≥2, 95.2%. Balloon-expandable valves were the most used valves.


Read also: Must Post MI Patients Use B Blockers for Life?


At 30 days, there were no differences in mortality, major bleeding, or life-threatening bleeding, but NOAC patients had higher rates of non-disabling stroke compared with VKA patients (1.2% vs. 0%; p < 0.001).

At 1 year, the primary endpoint was higher for NOAC patients (20.9% vs. 14.4%; hazard ratio [HR] 1.47; 95% confidence interval [CI]: 1.06 to 2.04; p 0 = 0.018); there were no differences as regards mortality, acute myocardial infarction, or bleeding. The rates of non-disabling stroke were higher for NOAC patients (1.6% vs. 0.3%; HR: 5.00; 95% CI: 0.97 to 25.81; p = 0.054).

Conclusion

Chronic use of NOACs and VKAs among patients in need of oral anticoagulation after TAVR resulted in comparable bleeding risk at 1 year. NOACs resulted in a higher ischemic event rate, something that should be evaluated in large randomized trials.

Courtesy of Dr. Carlos Fava.

Original Title: Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement.

Reference: David Jochheim, et al. JACC cardiovasc Interven. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...

Is Angioplasty Always Necessary after TAVR?

Courtesy of: Silvina E. Gomez, MD The prevalence of coronary artery disease (CAD) in patients undergoing TAVR is high, ranging from 40 to 70%, according...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions

The presence of coronary calcium significantly limits the success of percutaneous coronary interventions (PCI), primarily due to suboptimal stent expansion. This can lead to...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...